丙卡特罗口服溶液联合孟鲁司特片对儿童支气管哮喘疗效的影响  

Effect of Procaterol Oral Solution and Montelukast Tablets on Children’s Bronchial Asthma

作　　者：刘秋玲 LIU Qiu-ling(Depart-ment of Pediatrics,Mengzhou Second People's Hospital,Mengzhou,Henan,454750,China)

机构地区：[1]孟州市第二人民医院儿科,河南孟州454750

出　　处：《黑龙江医学》2022年第5期577-579,共3页Heilongjiang Medical Journal

摘　　要：目的:探究丙卡特罗口服溶液联合孟鲁司特片对儿童支气管哮喘的疗效。方法:选取2017年8月—2019年8月于孟州市第二人民医院诊治的288例支气管哮喘患儿作为研究对象,采用随机抽签法分为观察组和对照组,每组各144例。比较两组患儿支气管哮喘疗效、临床症状缓解时间、炎症因子水平、肺功能指标及用药期间副反应发生情况。结果:观察组患儿支气管哮喘治疗有效率(98.61%)高于对照组(93.75%),观察组肺部啰音、咳嗽、喘息及咳痰症状缓解时间均短于对照组,差异有统计学意义(t=11.493、17.154、14.093、19.258,P<0.05)。治疗前两组患儿炎症因子水平及肺功能指标比较,差异无统计学意义(t=0.276、0.261、0.333,P>0.05),治疗2周后观察组C反应蛋白(CRP)水平低于对照组,肺功能指标用力肺活量(FVC)、第1秒用力呼吸容积(FEV1)高于对照组。两组患儿支气管哮喘治疗期间副作用发生率差异无统计学意义(χ^(2)=0.204,P=0.652)。结论:丙卡特罗口服溶液联合孟鲁司特片可降低炎症因子水平,改善肺功能指标,安全性好,治疗儿童支气管哮喘效果显著。Objective: To explore the effect of procaterol oral solution combined with montelukast tablets on children with bronchial asthma. Methods: A total of 288 children with bronchial asthma who were diagnosed and treated in the hospital from August 2017 to August 2019 were selected as the research objects. They were divided into observation group and control group by random drawing method, with 144 cases in each group. The curative effect of bronchial asthma, the remission time of clinical symptoms, the level of inflammatory factors, the indicators of lung function and the occurrence of side effects during medication were compared between the two groups. Results: The effective rate of bronchial asthma treatment in the observation group(98.61%) was higher than that of the control group(93.75%). The relief time of lung rales, cough, wheezing, and sputum in the observation group was shorter than that in the control group, with statistically significant difference(t=11.493, 17.154, 14.093, 19.258, P<0.05). There was no statistically significant difference in the levels of inflammatory factors and lung function indexes between the two groups of children before treatment(t=0.276, 0.261, 0.333, P>0.05). After 2 weeks of treatment, the C-reactive protein(CRP) level of the observation group was lower than that of the control group, and the lung function indexes of forced vital capacity(FVC) and forced breathing volume in the first second(FEV1) were higher than those of the control group. There was no statistically significant difference in the incidence of side effects between the two groups of children with bronchial asthma during treatment(χ^(2)=0.204, P=0.652). Conclusion: Procaterol oral solution combined with montelukast tablets can reduce the level of inflammatory factors, improve lung function indicators, have good safety,and have a significant effect on the treatment of bronchial asthma in children.

关 键 词：丙卡特罗 孟鲁司特片 儿童支气管哮喘 临床疗效 

分 类 号：R322.34[医药卫生—人体解剖和组织胚胎学]